Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980684 | 0.85 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL6980709 | 0.84 | ITGB3 (0.71) | ITGB3ITGA2BPOLBITGAVITGB5 | |
| SCHEMBL7834692 | 0.82 | ITGB3 (0.54) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL6346049 | 0.80 | RAB9A (0.57) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL3141349 | 0.80 | ITGB3 (0.58) | ITGB3ITGA2BRAB9AMEN1KMT2A | |
| SCHEMBL5151908 | 0.79 | ITGB3 (0.57) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL688684 | 0.79 | ITGB3 (0.53) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL27182521 | 0.78 | ITGB3 (0.56) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL6344990 | 0.77 | RAB9A (0.54) | ITGB3ITGA2BRAB9ANPC1MEN1 | |
| SCHEMBL686712 | 0.76 | ITGB3 (0.52) | ITGB3ITGA2BRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949534-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2005-09-27 | — | — | US | claimed |
| US-20040053907-A1 | Cell adhesion inhibitors | BIOGEN, INC. A MASSACHUSETTS CORPORATION. | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ITGB3 21/4885ITGA2B 23/4885RAB9A 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.